Literature DB >> 6708928

The kinetics of competitive radioligand binding predicted by the law of mass action.

H J Motulsky, L C Mahan.   

Abstract

Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored. The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time. This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions. Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments. Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached. Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time. The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above. When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI. At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved. When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.

Mesh:

Year:  1984        PMID: 6708928

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  98 in total

Review 1.  Allosteric drugs acting at muscarinic acetylcholine receptors.

Authors:  Magali Waelbroeck
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 2.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Authors:  Dong Guo; Thea Mulder-Krieger; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

4.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

5.  Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.

Authors:  Angela Arsova; Thor C Møller; Line Vedel; Jakob Lerche Hansen; Simon R Foster; Karen J Gregory; Hans Bräuner-Osborne
Journal:  Mol Pharmacol       Date:  2020-05-01       Impact factor: 4.436

6.  Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes.

Authors:  Kang Yan; Lenore Madden; Anthony E Choudhry; Christine S Voigt; Robert A Copeland; Richard R Gontarek
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

7.  Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor.

Authors:  Mark R Dowling; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2006-07-10       Impact factor: 8.739

8.  Thermodynamic analysis of ligands at cholecystokinin CCK2 receptors in rat cerebral cortex.

Authors:  E A Harper; S P Roberts; S B Kalindjian
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 9.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

10.  Direct labelling of beta 2-adrenoceptors. Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551.

Authors:  H Lemoine; B Ehle; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.